Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

[2.2.1]-Bicyclic sultams as potent androgen receptor antagonists.

Shan W, Balog A, Nation A, Zhu X, Chen J, Cvijic ME, Geng J, Rizzo CA, Spires T Jr, Attar RM, Obermeier M, Traeger S, Dai J, Zhang Y, Galella M, Trainor G, Vite GD, Gavai AV.

Bioorg Med Chem Lett. 2016 Dec 1;26(23):5707-5711. doi: 10.1016/j.bmcl.2016.10.059. Epub 2016 Oct 21.

PMID:
27836399
2.

Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer.

Huang A, Jayaraman L, Fura A, Vite GD, Trainor GL, Gottardis MM, Spires TE, Spires VM, Rizzo CA, Obermeier MT, Elzinga PA, Todderud G, Fan Y, Newitt JA, Beyer SM, Zhu Y, Warrack BM, Goodenough AK, Tebben AJ, Doweyko AM, Gold DL, Balog A.

ACS Med Chem Lett. 2015 Dec 2;7(1):40-5. doi: 10.1021/acsmedchemlett.5b00310. eCollection 2016 Jan 14.

3.

Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists.

Xiao HY, Balog A, Attar RM, Fairfax D, Fleming LB, Holst CL, Martin GS, Rossiter LM, Chen J, Cvjic ME, Dell-John J, Geng J, Gottardis MM, Han WC, Nation A, Obermeier M, Rizzo CA, Schweizer L, Spires T Jr, Shan W, Gavai A, Salvati ME, Vite G.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4491-5. doi: 10.1016/j.bmcl.2010.06.034. Epub 2010 Jun 10.

PMID:
20584610
4.

Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer.

Attar RM, Jure-Kunkel M, Balog A, Cvijic ME, Dell-John J, Rizzo CA, Schweizer L, Spires TE, Platero JS, Obermeier M, Shan W, Salvati ME, Foster WR, Dinchuk J, Chen SJ, Vite G, Kramer R, Gottardis MM.

Cancer Res. 2009 Aug 15;69(16):6522-30. doi: 10.1158/0008-5472.CAN-09-1111. Epub 2009 Aug 4.

5.

Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.

Salvati ME, Balog A, Shan W, Rampulla R, Giese S, Mitt T, Furch JA, Vite GD, Attar RM, Jure-Kunkel M, Geng J, Rizzo CA, Gottardis MM, Krystek SR, Gougoutas J, Galella MA, Obermeier M, Fura A, Chandrasena G.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):1910-5. doi: 10.1016/j.bmcl.2008.02.006. Epub 2008 Feb 8.

PMID:
18291644
6.

The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.

Schweizer L, Rizzo CA, Spires TE, Platero JS, Wu Q, Lin TA, Gottardis MM, Attar RM.

BMC Cell Biol. 2008 Jan 24;9:4. doi: 10.1186/1471-2121-9-4.

7.

Pharmacological characterization of postjunctional alpha-adrenoceptors in human nasal mucosa.

Corboz MR, Rivelli MA, Varty L, Mutter J, Cartwright M, Rizzo CA, Eckel SP, Anthes JC, Hey JA.

Am J Rhinol. 2005 Sep-Oct;19(5):495-502.

PMID:
16270605
8.

Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3).

Spires TE, Fink BE, Kick EK, You D, Rizzo CA, Takenaka I, Lawrence RM, Ruan Z, Salvati ME, Vite GD, Weinmann R, Attar RM, Gottardis MM, Lorenzi MV.

Prostate. 2005 Oct 1;65(2):159-70.

PMID:
15924334
9.

Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.

Salvati ME, Balog A, Wei DD, Pickering D, Attar RM, Geng J, Rizzo CA, Hunt JT, Gottardis MM, Weinmann R, Martinez R.

Bioorg Med Chem Lett. 2005 Jan 17;15(2):389-93.

PMID:
15603960
10.

Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.

Salvati ME, Balog A, Shan W, Wei DD, Pickering D, Attar RM, Geng J, Rizzo CA, Gottardis MM, Weinmann R, Krystek SR, Sack J, An Y, Kish K.

Bioorg Med Chem Lett. 2005 Jan 17;15(2):271-6.

PMID:
15603938
11.

The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists.

Balog A, Salvati ME, Shan W, Mathur A, Leith LW, Wei DD, Attar RM, Geng J, Rizzo CA, Wang C, Krystek SR, Tokarski JS, Hunt JT, Gottardis M, Weinmann R.

Bioorg Med Chem Lett. 2004 Dec 20;14(24):6107-11.

PMID:
15546739
12.

Pharmacological characterization of alpha 2-adrenoceptor-mediated responses in pig nasal mucosa.

Corboz MR, Varty LM, Rizzo CA, Mutter JC, Rivelli MA, Wan Y, Umland S, Qiu H, Jakway J, McCormick KD, Berlin M, Hey JA.

Auton Autacoid Pharmacol. 2003 Aug;23(4):208-19.

PMID:
15084187
13.

Functional TRPV4 channels are expressed in human airway smooth muscle cells.

Jia Y, Wang X, Varty L, Rizzo CA, Yang R, Correll CC, Phelps PT, Egan RW, Hey JA.

Am J Physiol Lung Cell Mol Physiol. 2004 Aug;287(2):L272-8. Epub 2004 Apr 9.

14.

Increased blocking activity of combined tachykinin NK1- and NK2-receptor antagonists on tachykinergic bronchomotor responses in the guinea-pig.

Corboz MR, Fernandez X, Rizzo CA, Tozzi S, Monahan ME, Hey JA.

Auton Autacoid Pharmacol. 2003 Feb;23(1):79-93.

PMID:
14565542
15.

Development and potential utility of dual and triple NK receptor antagonists.

Rizzo CA, Anthes JC, Corboz MR, Chapman RW, Shih NY, Reichard GA, Ng KJ, Hey JA.

Curr Top Med Chem. 2003;3(12):1410-22. Review.

PMID:
12871172
16.

Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).

McLeod RL, Rizzo CA, West RE Jr, Aslanian R, McCormick K, Bryant M, Hsieh Y, Korfmacher W, Mingo GG, Varty L, Williams SM, Shih NY, Egan RW, Hey JA.

J Pharmacol Exp Ther. 2003 Jun;305(3):1037-44. Epub 2003 Mar 20.

17.

Coordination of histamine H3 receptor antagonists with human adrenal cytochrome P450 enzymes.

Yang R, Hey JA, Aslanian R, Rizzo CA.

Pharmacology. 2002 Nov;66(3):128-35.

PMID:
12372902
18.

Identification of a novel 1'-[5-((3,5-dichlorobenzoyl)methylamino)-3-(3,4-dichlorophenyl)-4-(methoxyimino)pentyl]-2-oxo-(1,4'-bipiperidine) as a dual NK(1)/NK(2) antagonist.

Ting PC, Lee JF, Shih NY, Piwinski JJ, Anthes JC, Chapman RW, Rizzo CA, Hey JA, Ng K, Nomeir AA.

Bioorg Med Chem Lett. 2002 Aug 19;12(16):2125-8.

PMID:
12127519
19.

Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor.

Billah MM, Cooper N, Minnicozzi M, Warneck J, Wang P, Hey JA, Kreutner W, Rizzo CA, Smith SR, Young S, Chapman RW, Dyke H, Shih NY, Piwinski JJ, Cuss FM, Montana J, Ganguly AK, Egan RW.

J Pharmacol Exp Ther. 2002 Jul;302(1):127-37.

20.

The IL-5 receptor on human bronchus selectively primes for hyperresponsiveness.

Rizzo CA, Yang R, Greenfeder S, Egan RW, Pauwels RA, Hey JA.

J Allergy Clin Immunol. 2002 Mar;109(3):404-9.

PMID:
11897983
21.

Nociceptin/orphanin FQ inhibits capsaicin-induced guinea-pig airway contraction through an inward-rectifier potassium channel.

Jia Y, Wang X, Aponte SI, Rivelli MA, Yang R, Rizzo CA, Corboz MR, Priestley T, Hey JA.

Br J Pharmacol. 2002 Feb;135(3):764-70.

22.

Synergistic antiallergic activity of combined histamine H1- and cysteinyl leukotriene1-receptor blockade in human bronchus.

Ruck LM, Rizzo CA, Anthes JC, Eckel S, Egan RW, Cuss FM, Hey JA.

Life Sci. 2001 May 11;68(25):2825-34.

PMID:
11432448
23.

Postjunctional alpha(2C)-adrenoceptor contractility in human saphenous vein.

Rizzo CA, Ruck LM, Corboz MR, Umland SP, Wan Y, Shah H, Jakway J, Cheng L, McCormick K, Egan RW, Hey JA.

Eur J Pharmacol. 2001 Feb 16;413(2-3):263-9.

PMID:
11226402
24.
25.

NK(2)-receptor mediated contraction in monkey, guinea-pig and human airway smooth muscle.

Rizzo CA, Valentine AF, Egan RW, Kreutner W, Hey JA.

Neuropeptides. 1999 Feb;33(1):27-34.

PMID:
10657468
26.

Pharmacological characterization of histamine H3 receptors in human saphenous vein and guinea pig ileum.

Valentine AF, Rizzo CA, Rivelli MA, Hey JA.

Eur J Pharmacol. 1999 Jan 29;366(1):73-8.

PMID:
10064154
27.

Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971.

Hey JA, Aslanian R, Bolser DC, Chapman RW, Egan RW, Rizzo CA, Shih NY, Fernandez X, McLeod RL, West R, Kreutner W.

Arzneimittelforschung. 1998 Sep;48(9):881-8.

PMID:
9793613
28.

Tachykinin NK1 receptor-mediated vasorelaxation in human pulmonary arteries.

Corboz MR, Rivelli MA, Ramos SI, Rizzo CA, Hey JA.

Eur J Pharmacol. 1998 May 29;350(1):R1-3.

PMID:
9683025
29.

Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses.

Caamaño JH, Rizzo CA, Durham SK, Barton DS, Raventós-Suárez C, Snapper CM, Bravo R.

J Exp Med. 1998 Jan 19;187(2):185-96.

30.

Airway eosinophils, T cells, Th2-type cytokine mRNA, and hyperreactivity in response to aerosol challenge of allergic mice with previously established pulmonary inflammation.

Garlisi CG, Falcone A, Hey JA, Paster TM, Fernandez X, Rizzo CA, Minnicozzi M, Jones H, Billah MM, Egan RW, Umland SP.

Am J Respir Cell Mol Biol. 1997 Nov;17(5):642-51.

PMID:
9374116
31.

The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice.

Carrasco D, Rizzo CA, Dorfman K, Bravo R.

EMBO J. 1996 Jul 15;15(14):3640-50.

32.

Expression of FosB during mouse development: normal development of FosB knockout mice.

Gruda MC, van Amsterdam J, Rizzo CA, Durham SK, Lira S, Bravo R.

Oncogene. 1996 May 16;12(10):2177-85.

PMID:
8668344
33.

Pharmacological characterization of histamine H3 receptors in isolated guinea pig pulmonary artery and ileum.

Rizzo CA, Tozzi S, Monahan ME, Hey JA.

Eur J Pharmacol. 1995 Dec 27;294(1):329-35.

PMID:
8788448
34.

Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family.

Weih F, Carrasco D, Durham SK, Barton DS, Rizzo CA, Ryseck RP, Lira SA, Bravo R.

Cell. 1995 Jan 27;80(2):331-40.

35.

Further evidence for prejunctional GABA-B inhibition of cholinergic and peptidergic bronchoconstriction in guinea pigs: studies with new agonists and antagonists.

Chapman RW, Danko G, del Prado M, Egan RW, Kreutner W, Rizzo CA, Hey JA.

Pharmacology. 1993 Jun;46(6):315-23.

PMID:
8390694
36.

5-HT3 receptors augment neuronal, cholinergic contractions in guinea pig trachea.

Rizzo CA, Kreutner W, Chapman RW.

Eur J Pharmacol. 1993 Mar 30;234(1):109-12. Erratum in: Eur J Pharmacol 1993 Aug 24;240(2-3):327.

PMID:
8472753
37.

GABAB receptors in the lung.

Chapman RW, Hey JA, Rizzo CA, Bolser DC.

Trends Pharmacol Sci. 1993 Jan;14(1):26-9. Review.

PMID:
8382886
38.

Both products of the fosB gene, FosB and its short form, FosB/SF, are transcriptional activators in fibroblasts.

Dobrazanski P, Noguchi T, Kovary K, Rizzo CA, Lazo PS, Bravo R.

Mol Cell Biol. 1991 Nov;11(11):5470-8.

39.

Constitutive expression of FosB and its short form, FosB/SF, induces malignant cell transformation in rat-1A cells.

Kovary K, Rizzo CA, Ryseck RP, Noguchi T, Raynoschek C, Pelosin JM, Bravo R.

New Biol. 1991 Sep;3(9):870-9.

PMID:
1931831

Supplemental Content

Loading ...
Support Center